Welcome to our dedicated page for Sensei Biotherapeutics SEC filings (Ticker: SNSE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Sensei Biotherapeutics, Inc. (SNSE) provide structured insight into how this clinical stage biotechnology company reports its operations, clinical progress, and corporate actions. Sensei’s common stock is registered on The Nasdaq Stock Market LLC under the symbol SNSE, and the company uses a range of SEC forms to communicate with investors and regulators.
Sensei frequently files Form 8-K to furnish press releases on quarterly financial results and other material events. These filings typically include information on research and development (R&D) and general and administrative (G&A) expenses, cash, cash equivalents and marketable securities, and net loss, along with narrative discussion of clinical milestones. For example, 8-Ks have been used to report financial results for quarters ended March 31, June 30, and September 30, and to attach corresponding press releases as exhibits.
The company also uses Form 8-K to disclose clinical and corporate developments. Filings have furnished press releases on new clinical data for solnerstotug in PD-(L)1 resistant tumors, including presentations at the ESMO Congress, and updates to corporate presentations. Other 8-Ks have described a 1-for-20 reverse stock split intended to help regain compliance with Nasdaq’s minimum bid price requirement and Nasdaq’s subsequent confirmation that Sensei had regained compliance with Listing Rule 5550(a)(2).
A notable 8-K dated October 30, 2025, furnishes a press release announcing that Sensei’s Board of Directors decided to discontinue development of solnerstotug and initiate a strategic review of alternatives, which may include asset sales, licensing, collaborations, a sale of the company, a business combination, a merger, or an orderly wind-down of operations. This filing illustrates how SEC documents capture shifts in corporate strategy and potential changes in the company’s future operations.
On this page, SNSE investors can review Sensei’s SEC filings as they are made available from EDGAR. AI-powered summaries can help explain the key points in lengthy filings, highlight changes in financial condition, and clarify the implications of material events, while the underlying documents remain the authoritative source for detailed information.
Sensei Biotherapeutics, Inc. reports 2025 results showing a net loss of $21.1 million, down from $30.2 million in 2024, as both research and development and general and administrative expenses declined. Cash, cash equivalents and marketable securities totaled $21.2 million as of December 31, 2025.
In February 2026, Sensei acquired Faeth Therapeutics, bringing lead asset PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor, into its pipeline and raising $200 million in a private placement. The auditor highlighted substantial doubt about Sensei’s ability to continue as a going concern due to potential cash obligations tied to convertible Series B preferred stock.
Sensei Biotherapeutics reported full-year 2025 results and highlighted its strategic shift following the Faeth Therapeutics acquisition and a $200 million private placement. PIKTOR, an all-oral combination targeting the PI3K/AKT/mTOR pathway, is now the lead program in endometrial and HR+/HER2- advanced breast cancer.
Cash, cash equivalents and marketable securities were $21.2 million as of December 31, 2025. R&D expenses fell to $11.0 million from $18.6 million and G&A to $11.3 million from $13.0 million, helping narrow net loss to $21.1 million, or $(16.72) per share, from $30.2 million, or $(24.01) per share.
Sensei Biotherapeutics ownership disclosure: Trails Edge entities and Ortav Yehudai report beneficial ownership of 126,010 shares, representing 9.9% of common stock as of February 18, 2026.
The reported 126,010 shares comprise 125,000 shares held directly by Trails Edge Biotechnology and 1,010 shares underlying Series B Convertible Stock. The filing states 360,000 shares underlying additional Series B Preferred Shares are excluded from this count due to an issuance limitation that prevents conversion above 9.99%. The ownership percentage is calculated using 1,261,290 shares outstanding as of November 10, 2025 per the issuer's Form 10-Q.
SNSE submitted a Form 144 notice reporting a proposed Rule 144 sale of 3,374 common shares to be effected on 02/24/2026 pursuant to an option granted on 02/15/2023. The filing also discloses prior sales of 42,594 common shares on 02/19/2026 for $1,094,370.79.
Sensei Biotherapeutics, Inc. reported that Chief Operating Officer Anand Kiran Parikh acquired several equity awards in connection with the Faeth transaction and new compensation grants. On February 19, 2026, he received 1,239,305 employee stock options with a stated price of $0.00 per share. On February 17, 2026, he acquired 809,822 shares of Series B Non-Voting Convertible Preferred Stock and additional employee stock options covering 92,533 and 56,673 shares, all recorded as awards at $0.00 per share.
Footnotes explain that each share of Series B Preferred Stock is convertible into 1,000 shares of common stock with no expiration date and was received in exchange for 4,062,777 shares of Faeth Holdings Therapeutics, Inc. common stock under a Merger Agreement among Sensei, two Sapphire Merger Subs, HoldCo and Faeth. Other footnotes state that certain options were received in exchange for Faeth stock options with a $0.23 exercise price, with one such option vesting in 48 equal monthly installments beginning August 1, 2022. A separate option grant is immediately exercisable, while another vests 25% on February 19, 2027 and the remainder in 36 equal monthly installments thereafter.
Sensei Biotherapeutics, Inc. filed an initial insider ownership report for Parikh Anand Kiran. The filing identifies him as both a director and the Chief Operating Officer of the company. This Form 3 does not report any specific stock transactions or share amounts.
James Peyer filed a Form 144 reporting a proposed sale of 950 common shares on 02/18/2026. The filing lists the sale as an option granted 06/11/2024 and names Fidelity Brokerage Services LLC as the broker. The excerpt also shows prior sales of 841 common shares on 12/09/2025 for $6,706.72.
Sensei Biotherapeutics is transforming its business by acquiring Faeth Therapeutics and raising about $200 million in a concurrent private placement of Series B non-voting convertible preferred stock. These preferred shares are each convertible into 1,000 common shares if stockholders later approve the needed proposals.
After the merger and financing, former Faeth holders and new investors will own the vast majority of Sensei, while existing stockholders drop to about 4.9% of the fully diluted common stock. The deal makes Faeth’s lead cancer drug PIKTOR Sensei’s main program, with funding aimed at Phase 2 endometrial cancer data and a Phase 1b breast cancer trial by year-end 2026.
Donenberg Phillip B. reported acquisition or exercise transactions in a Form 4 filing for SNSE. The filing lists transactions totaling 1,900 shares. Following the reported transactions, holdings were 1,900 shares.
Sensei Biotherapeutics, Inc. director Phillip B. Donenberg filed an initial Form 3 reporting his beneficial ownership of the company’s securities as of February 13, 2026. The filing states that no securities are beneficially owned and lists no derivative positions or transactions.